Insight, China's Pharmaceutical Industry

Company Drug

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 TRANSCEND‑T2D‑1...

Company Drug

Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer

Fineline Cube Mar 20, 2026

Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 TALAPRO-3 study, demonstrating...

Others

Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data

Fineline Cube Mar 20, 2026

Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901...

Company Deals

Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36

Fineline Cube Mar 20, 2026

Samsung Bioepis Co., Ltd. has expanded its strategic partnership with Sandoz AG (SWX: SDZ), entering...

Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Fineline Cube Mar 19, 2026

Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that ABSK061 received Orphan Drug Designation (ODD) from...

Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Fineline Cube Mar 19, 2026

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced the initiation of a Phase III clinical...

Company Drug

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

Fineline Cube Mar 19, 2026

Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate...

Company Drug

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Fineline Cube Mar 19, 2026

InventisBio (Shanghai) Co., Ltd. (SHA: 688382) announced FDA clearance to initiate a Phase II clinical...

Company Drug

Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo

Fineline Cube Mar 19, 2026

Suzhou Kintor Pharmaceuticals, Inc. (HKG: 9939) announced that its pivotal Phase III clinical study for...

Medical Device

Super Vision Technology Wins NMPA Approval for Ocular Neurostimulator – First-in-Class Implantable Device Treats Congenital Nystagmus

Fineline Cube Mar 19, 2026

Super Vision Technology, Inc. announced National Medical Products Administration (NMPA) approval for its implantable ocular...

Company Deals Medical Device

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Fineline Cube Mar 19, 2026

GE HealthCare (NASDAQ: GEHC) announced completion of the acquisition of Intelerad, a leading medical imaging...

Company Deals

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

Fineline Cube Mar 19, 2026

Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, announced a...

Company Drug

J&J’s Icotyde Wins FDA Approval – First Oral IL-23 Receptor Antagonist Targets Moderate-to-Severe Plaque Psoriasis

Fineline Cube Mar 19, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced FDA marketing approval for Icotyde (icotrokinra), an interleukin-23...

Company Drug

Sanofi’s Venglustat Wins FDA Breakthrough Therapy Designation – Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms

Fineline Cube Mar 19, 2026

Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food...

Company Deals

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

Fineline Cube Mar 19, 2026

Sipai Health Technology Co., Ltd. (HKG: 0314), operating as Medbanks, announced the acquisition of 100%...

Company Drug

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

Fineline Cube Mar 19, 2026

TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced first patient dosing in a Phase II clinical...

Company Deals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Fineline Cube Mar 19, 2026

Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751...

Company Deals

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Fineline Cube Mar 19, 2026

Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ:...

Policy / Regulatory

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Fineline Cube Mar 19, 2026

The US Food and Drug Administration (FDA) has advanced its “Roadmap to Reducing Animal Testing...

Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Fineline Cube Mar 18, 2026

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China’s...

Insight, China's Pharmaceutical Industry

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer

Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data

Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo

Super Vision Technology Wins NMPA Approval for Ocular Neurostimulator – First-in-Class Implantable Device Treats Congenital Nystagmus

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

J&J’s Icotyde Wins FDA Approval – First Oral IL-23 Receptor Antagonist Targets Moderate-to-Severe Plaque Psoriasis

Sanofi’s Venglustat Wins FDA Breakthrough Therapy Designation – Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

You Missed

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards